ANSWER: C

Rationale:

The plateau exists because an S-phase-specific agent can only kill cells that are synthesizing DNA during the exposure window; once those cells are killed, additional drug has no further target until new cells enter S phase. The direct scheduling consequence is that increasing the duration of exposure, not the size of a single dose, increases total cell kill. Prolonged infusion or repeated dosing keeps cytotoxic concentrations present as successive cohorts of cells enter S phase, which is the pharmacologic basis for continuous-infusion regimens of S-phase agents. This is the discrimination a clinician must make: for a phase-specific drug, schedule governs efficacy, whereas for a cycle-nonspecific drug, total dose governs efficacy over a wider range.

• Option A: Option A is incorrect because escalating a single bolus beyond the plateau dose adds toxicity without additional cell kill; the plateau is precisely the reason bolus escalation fails.
• Option B: Option B inverts the biology: S-phase agents are most effective against high-growth-fraction tumors with many cycling cells, not low-growth-fraction tumors.
• Option D: Option D is incorrect because adding a second S-phase agent does not abolish the plateau inherent to phase-specific killing; the plateau is overcome by extending exposure time, not by stacking same-phase drugs.
• Option E: Option E is incorrect because scheduling is highly relevant for S-phase agents; the plateau is the very feature that makes prolonged exposure, rather than dose, the determinant of kill.

ANSWER: A

Rationale:

Cycle-nonspecific agents — principally the alkylating agents and the platinum compounds — damage DNA in a manner that does not require the cell to be traversing a particular phase, so they kill cycling and quiescent (G0) cells alike. Because their lethality is not gated by phase availability, their dose-response relationship is more nearly linear over a wider dose range than that of phase-specific agents: increasing the dose continues to increase cell kill rather than reaching an early plateau. This is why these agents retain activity against indolent, low-growth-fraction tumors that resist phase-specific drugs, and why dose intensity is a more direct determinant of their effect.

• Option B: Option B describes a cycle-specific (S-phase) agent, the opposite of the class in question.
• Option C: Option C describes M-phase-specific agents such as the vinca alkaloids, which require spindle assembly to act; cycle-nonspecific agents do not.
• Option D: Option D is incorrect because cycle-nonspecific agents are notable precisely for retaining activity against low-growth-fraction tumors, not for requiring very high growth fractions.
• Option E: Option E is incorrect because cycle-nonspecific agents kill G0 cells rather than sparing them, and the prolonged-infusion rationale applies to phase-specific agents, not to this class.

ANSWER: D

Rationale:

The Norton-Simon hypothesis extends Gompertzian kinetics to scheduling. After each cycle, the surviving tumor cell population is reduced and small, which places it in the high-growth-fraction, near-exponential portion of the Gompertz curve, so it regrows rapidly during the recovery interval. Compressing the interval between cycles — the definition of dose density — shortens the window available for this rapid regrowth, so that the next cycle strikes before the residual disease has rebounded. This is the mechanistic prediction that justifies dose-dense scheduling: the benefit comes from denying residual disease its regrowth period, not from raising the per-cycle dose. The strategy requires growth-factor support to be feasible, because the shortened interval would otherwise force delay from cumulative myelosuppression.

• Option A: Option A describes high-dose therapy with stem cell rescue, a distinct strategy based on per-cycle dose escalation, not the interval-compression logic of Norton-Simon.
• Option B: Option B incorrectly contradicts the hypothesis, which depends on the premise that residual disease regrows briskly between cycles.
• Option C: Option C inverts the prediction: shortening, not lengthening, the interval suppresses regrowth, and the Norton-Simon argument is about regrowth kinetics rather than resistance emergence.
• Option E: Option E is incorrect because the hypothesis specifically holds that the spacing of doses matters; identical cumulative doses produce different outcomes depending on interval, which is the entire rationale for dose density.

ANSWER: B

Rationale:

P-glycoprotein is an ATP-driven efflux pump with an unusually broad substrate range that explains the cross-resistance pattern of classic multidrug resistance. It avidly transports structurally unrelated hydrophobic compounds out of the cell, including the anthracyclines, the vinca alkaloids, the taxanes, and the epipodophyllotoxins such as etoposide and teniposide, as well as many tyrosine kinase inhibitors. Because a single pump handles all of these, overexpression confers simultaneous resistance to several drug classes that share no common structure or mechanism, which is the defining feature of the multidrug-resistant phenotype and a key consideration when selecting agents for a salvage regimen.

• Option A: Option A is incorrect because small hydrophilic, renally cleared agents such as carboplatin, cisplatin, and methotrexate are not characteristic P-glycoprotein substrates; the pump favors larger hydrophobic molecules.
• Option C: Option C understates the substrate range; the clinical importance of P-glycoprotein is precisely its broad cross-resistance, not anthracycline-only handling.
• Option D: Option D is incorrect because the classic alkylating agents and nitrosoureas are not the defining P-glycoprotein substrates; the natural-product–derived hydrophobic agents are.
• Option E: Option E is incorrect because high-molecular-weight biologics such as cytokines and antibodies are not transported by P-glycoprotein, which handles small-to-intermediate hydrophobic molecules.

ANSWER: E

Rationale:

BCRP (ABCG2), the breast cancer resistance protein, is an ATP-binding cassette efflux transporter notable for high expression in hematopoietic stem cells, where it contributes to the protected, drug-resistant phenotype of that compartment. Its substrate profile is distinct from that of P-glycoprotein and includes mitoxantrone, the camptothecin-derived topoisomerase I inhibitors irinotecan and topotecan, and several orally administered kinase inhibitors such as imatinib and gefitinib. Recognizing which pump handles which agents is the precise discrimination required when interpreting a resistant phenotype, because the transporter expressed determines which salvage agents are likely to remain effective.

• Option A: Option A describes MRP1 (ABCC1), which transports organic anions and glutathione conjugates and is associated with anthracycline, vinca, and methotrexate resistance, not BCRP.
• Option B: Option B describes copper transporter 1 (CTR1), the influx transporter whose reduced expression lowers cisplatin uptake, which is a platinum-handling mechanism rather than an efflux pump.
• Option C: Option C describes deoxycytidine kinase, an activating enzyme for cytarabine, not a transporter.
• Option D: Option D describes a transcription factor such as p53, which is part of the apoptosis-defect category of resistance, not an ABC transporter.

ANSWER: C

Rationale:

DPD is the principal enzyme that catabolizes 5-fluorouracil to inactive metabolites. When DPD activity is genetically deficient — a state affecting a small percentage of the population — standard doses of 5-FU are not adequately broken down, so the drug accumulates to markedly elevated exposures and produces severe, sometimes fatal toxicity, including profound myelosuppression, mucositis, and neurotoxicity. This is the toxicity end of the spectrum. The resistance end is the mirror image: tumor overexpression of DPD accelerates catabolism of 5-FU within the tumor and correlates with clinical resistance. The clinician must hold both ends of this single enzyme axis in mind, because the same metabolic step explains both unexpected severe toxicity in a deficient patient and reduced efficacy in a tumor that overexpresses the enzyme.

• Option A: Option A reverses the role of DPD, which catabolizes (inactivates) 5-FU rather than activating it, so overexpression reduces exposure rather than causing systemic toxicity.
• Option B: Option B is incorrect because DPD deficiency increases drug exposure and toxicity; it does not confer resistance, and DPD is a catabolic, not an activating, enzyme.
• Option D: Option D is incorrect because DPD deficiency has profound clinical consequences, and 5-FU disposition is governed by DPD-mediated catabolism rather than purely renal excretion.
• Option E: Option E inverts the relationship: tumor DPD overexpression is associated with resistance, and it is DPD deficiency, not overexpression, that drives severe host toxicity.

ANSWER: A

Rationale:

Methotrexate is cleared almost entirely by the kidney, by both glomerular filtration and active tubular secretion. NSAIDs, and similarly proton pump inhibitors, interfere with the renal tubular secretion of methotrexate, slowing its elimination and prolonging systemic exposure. Because the toxicity of methotrexate is exposure-dependent, this delayed clearance can precipitate severe mucositis and myelosuppression, and the danger is greatest with high-dose methotrexate, where the margin for prolonged exposure is narrowest. This is one of the small set of pharmacokinetic interactions that account for a disproportionate share of preventable methotrexate toxicity, and it is the reason these co-medications are scrutinized before high-dose administration.

• Option B: Option B reverses the direction of the interaction: the interaction delays clearance and raises exposure rather than accelerating elimination.
• Option C: Option C is incorrect because NSAIDs do not act at dihydrofolate reductase; the interaction is pharmacokinetic, occurring at the renal tubule, not pharmacodynamic at the target enzyme.
• Option D: Option D is incorrect because methotrexate is not converted into an alkylating metabolite by NSAIDs; the harm comes from prolonged exposure to methotrexate itself.
• Option E: Option E is incorrect because the interaction does not increase the volume of distribution or reduce toxicity; it raises exposure and increases toxicity.

ANSWER: D

Rationale:

Methotrexate is a hydrophilic, water-soluble drug, and a large third-space collection such as a pleural effusion or malignant ascites behaves as a reservoir into which the drug distributes. After the plasma concentration falls, drug sequestered in that compartment is slowly released back into the systemic circulation, prolonging exposure well beyond the expected duration and increasing the risk of mucositis and myelosuppression without a proportional gain in antitumor effect. For this reason, large effusions or ascites should be drained before high-dose methotrexate so that the third-space reservoir does not convert a controlled exposure into a dangerously prolonged one. This is the canonical example of how a distribution compartment, not a clearance defect, drives unexpected toxicity.

• Option A: Option A is incorrect because the effusion does not accelerate metabolism; it acts as a slow-release reservoir that prolongs exposure.
• Option B: Option B is incorrect because methotrexate is not irreversibly bound and inactivated by the fluid; it redistributes back into the circulation in active form.
• Option C: Option C overstates the effect; the issue is delayed redistribution producing prolonged exposure, not the absence of any measurable plasma concentration.
• Option E: Option E is incorrect because the mechanism is third-space sequestration and slow release, not mechanical ureteral obstruction.

ANSWER: B

Rationale:

Carboplatin clearance tracks closely with glomerular filtration rate because the drug is eliminated predominantly by renal filtration. The Calvert formula exploits this by setting the dose to achieve a defined target AUC as a function of GFR, so that patients with differing renal function receive doses calibrated to deliver the same drug exposure. Body-surface-area dosing ignores the dominant determinant of carboplatin clearance and therefore systematically underdoses patients with high renal clearance, who eliminate the drug quickly, and overdoses patients with impaired renal function, who would otherwise accumulate toxic concentrations. Targeting exposure directly is what makes carboplatin one of the best-established examples of pharmacokinetically guided dosing in routine practice.

• Option A: Option A is incorrect because body-surface area does not capture renal function; that omission is precisely the deficiency the Calvert formula corrects.
• Option C: Option C inverts the logic of the formula, which depends critically on knowing GFR as its central input.
• Option D: Option D misidentifies the constant of 25, which approximates non-renal (extrarenal) clearance added to GFR, not a hepatic clearance term in the sense implied, and certainly not the basis of the formula's advantage.
• Option E: Option E is incorrect because the Calvert formula concerns dose calculation, not route; carboplatin is administered intravenously.

ANSWER: E

Rationale:

Anthracyclines, vinca alkaloids, taxanes, and irinotecan are cleared predominantly by hepatic metabolism and biliary excretion, so impaired hepatobiliary function reduces their clearance and raises exposure. Serum bilirubin is the standard surrogate for biliary excretory function used to guide dose reduction, and the dose is reduced as bilirubin rises. For doxorubicin, guidelines commonly recommend roughly a 50 percent reduction when total bilirubin is 1.2 to 3.0 mg/dL and roughly a 75 percent reduction when bilirubin exceeds 3.0 mg/dL. These thresholds are practical risk-management conventions rather than precisely derived pharmacokinetic targets, and they require the clinician to weigh the risk of undertreatment against the risk of severe toxicity from impaired clearance.

• Option A: Option A is incorrect because serum creatinine reflects renal, not hepatic, function, and the dose of a hepatically cleared agent is reduced, not increased, with worsening organ function.
• Option B: Option B is incorrect because while hypoalbuminemia can affect free drug fraction, albumin is not the standard parameter for anthracycline dose modification, and holding the dose constant ignores the clearance defect.
• Option C: Option C is incorrect because serum potassium does not guide hepatic dose adjustment.
• Option D: Option D is incorrect because although prothrombin time reflects hepatic synthetic function, it is not the standard dose-adjustment surrogate for these agents, and escalating the dose in hepatic impairment would be dangerous.

ANSWER: A

Rationale:

Vinca alkaloid extravasation is managed with warm compresses and local hyaluronidase, which promote dispersion and absorption of the extravasated drug. Cooling is specifically contraindicated for the vinca alkaloids because cold promotes local crystallization of the drug in the tissue and worsens the injury. This is the deliberate point of contrast with anthracycline extravasation, where the management is the opposite in key respects: dexrazoxane is the antidote, and cooling is avoided for a different reason (it reduces dexrazoxane delivery). The clinician must keep the agent-specific protocols distinct, because applying the anthracycline approach to a vinca extravasation, or vice versa, is harmful.

• Option B: Option B incorrectly applies the anthracycline protocol (cold plus dexrazoxane) to a vinca alkaloid, which would worsen the vinca injury through cooling.
• Option C: Option C describes the management of mechlorethamine extravasation (sodium thiosulfate), not vinca alkaloids.
• Option D: Option D is incorrect and dangerous because vinca alkaloids are vesicants capable of causing significant tissue injury, not harmless irritants.
• Option E: Option E inverts the correct thermal management: warming, not cooling, is indicated for vinca extravasation, and cold is the contraindicated maneuver.

ANSWER: C

Rationale:

Anthracycline tissue toxicity is driven substantially by iron-mediated generation of reactive free radicals and by topoisomerase II-mediated DNA damage in the exposed tissue. Dexrazoxane works on both: it chelates iron, reducing the iron-catalyzed free-radical injury, and it inhibits topoisomerase II in the affected tissue. This dual mechanism is why it is the specific antidote for anthracycline extravasation, and the six-hour administration window reflects the need to intervene before the iron-mediated cascade has produced irreversible damage. Understanding the mechanism explains both the choice of agent and the urgency of the time limit, and distinguishes dexrazoxane from agents that act by direct chemical neutralization.

• Option A: Option A is incorrect because dexrazoxane does not act by dilution; its effect is biochemical, through iron chelation and topoisomerase II inhibition.
• Option B: Option B describes direct chemical neutralization, the mechanism of sodium thiosulfate for mechlorethamine, which is not how dexrazoxane works.
• Option D: Option D is incorrect because dexrazoxane does not act primarily by accelerating renal clearance; the relevant injury is local and iron-mediated.
• Option E: Option E is incorrect because dexrazoxane does not work by promoting neutrophil-mediated debridement; it limits the free-radical and topoisomerase-mediated injury at its source.

ANSWER: D

Rationale:

Filgrastim is a non-glycosylated recombinant G-CSF eliminated primarily by renal clearance, giving it a short half-life of roughly 3.5 hours and requiring daily subcutaneous injection. Conjugation to a 20-kilodalton polyethylene glycol molecule dramatically reduces this renal clearance, because the enlarged molecule is filtered far less efficiently, prolonging the half-life to approximately 33 hours. The practical advantage is single per-cycle dosing: one injection of pegfilgrastim covers the period that would otherwise require multiple daily filgrastim injections. Recognizing that the PEG moiety acts by reducing renal elimination, rather than by changing receptor binding or route of administration, is the precise pharmacokinetic discrimination this question targets.

• Option A: Option A reverses the effect: PEGylation reduces renal clearance and lengthens, rather than shortens, the half-life.
• Option B: Option B is incorrect because PEGylation has a major pharmacokinetic effect on clearance; its purpose is not merely to reduce injection-site pain.
• Option C: Option C is incorrect because pegfilgrastim remains a subcutaneous injection; PEGylation does not confer oral bioavailability.
• Option E: Option E is incorrect because pegfilgrastim retains G-CSF receptor binding and biological activity; the PEG moiety alters clearance, not target engagement.

ANSWER: B

Rationale:

High-risk febrile neutropenia requires prompt hospital admission and empiric intravenous therapy with an anti-pseudomonal beta-lactam, because gram-negative organisms including Pseudomonas can cause rapid, fatal deterioration in the neutropenic host. Piperacillin-tazobactam is the most common first-line choice in institutional protocols, with a carbapenem reserved for patients who have a history of resistant organisms or who are deteriorating clinically. The defining contrast a clinician must recognize is between low-risk febrile neutropenia, where oral outpatient management can be appropriate, and high-risk febrile neutropenia, which mandates intravenous anti-pseudomonal coverage in the hospital. Empiric therapy must be started within an hour of presentation, before culture data are available.

• Option A: Option A describes the appropriate management of low-risk febrile neutropenia, which is unsafe to apply to a high-risk patient.
• Option C: Option C is incorrect because empiric antibacterial coverage, not a single antifungal dose, is the immediate priority; antifungal therapy is added later for persistent fever, not as initial monotherapy.
• Option D: Option D is incorrect and dangerous because therapy must begin empirically within an hour, not after cultures return.
• Option E: Option E is incorrect because empiric coverage must include anti-pseudomonal gram-negative activity; restricting to gram-positive organisms leaves the most dangerous pathogens uncovered.

ANSWER: E

Rationale:

Allopurinol is a xanthine oxidase inhibitor: it blocks the conversion of hypoxanthine and xanthine to uric acid, preventing new uric acid formation, but it does nothing to the uric acid that is already present. Rasburicase is recombinant urate oxidase: it enzymatically degrades existing uric acid to allantoin, a highly soluble product that is readily excreted, and therefore rapidly lowers an elevated uric acid burden. The clinical consequence of this distinction is decisive: for a patient who already has a high uric acid load and high tumor lysis risk, rasburicase is preferred because it removes the existing burden, whereas allopurinol alone would leave that burden in place while only preventing further accumulation. This mechanistic discrimination directly governs drug selection.

• Option A: Option A is incorrect because the drugs are not interchangeable; only rasburicase degrades existing uric acid, and the baseline level is exactly what determines the preferred agent.
• Option B: Option B reverses the two mechanisms.
• Option C: Option C is incorrect because rasburicase is not a xanthine oxidase inhibitor; it is urate oxidase, and the two drugs act at different points.
• Option D: Option D reverses the mechanisms, incorrectly attributing xanthine oxidase inhibition to rasburicase and uric acid degradation to allopurinol.

ANSWER: A

Rationale:

Methotrexate resistance classically involves amplification of the dihydrofolate reductase gene: the tumor produces so much target enzyme that achievable drug concentrations cannot inhibit all of it, leaving enough uninhibited enzyme to sustain folate metabolism and DNA synthesis. Cisplatin resistance, by contrast, is governed substantially by platinum handling at the membrane: reduced expression of the copper influx transporter CTR1, which mediates cisplatin uptake, combined with increased expression of copper-exporting transporters such as ATP7A and ATP7B, lowers intracellular platinum accumulation. Correctly pairing each drug with its mechanism is the precise discrimination required, because the resistance route determines which salvage strategies and biomarkers are relevant for each agent.

• Option B: Option B incorrectly swaps the two mechanisms, assigning CTR1-mediated uptake loss to methotrexate and dihydrofolate reductase amplification to cisplatin.
• Option C: Option C is incorrect because neither methotrexate nor cisplatin is principally a P-glycoprotein substrate; their resistance mechanisms are target amplification and altered platinum transport, respectively.
• Option D: Option D incorrectly misassigns mechanisms, attributing copper export to methotrexate and deoxycytidine kinase loss (a cytarabine mechanism) to cisplatin.
• Option E: Option E is incorrect because dihydropyrimidine dehydrogenase overexpression is a 5-fluorouracil resistance mechanism, not a mechanism for either methotrexate or cisplatin.